iShares Biotechnology ETF
1,029 hedge funds and large institutions have $9.09B invested in iShares Biotechnology ETF in 2026 Q3 according to their latest regulatory filings, with 150 funds opening new positions, 295 increasing their positions, 277 reducing their positions, and 58 closing their positions.
159% more first-time investments, than exits
New positions opened: 150 | Existing positions closed: 58
60% more capital inflows, than outflows
Capital inflows: $1.39B | Capital outflows: $868M
28% more call options, than puts
Call options by funds: $250M | Put options by funds: $195M
7% more funds holding
Funds holding: 964 → 1,029 (+65)
6% more repeat investments, than reductions
Existing positions increased: 295 | Existing positions reduced: 277
1.26% less ownership
Funds ownership: 85.88% → 84.62% (-1.3%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$446M |
| 2 |
Morgan Stanley
New York
|
+$183M |
| 3 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$55.4M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$48.5M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$41.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$297M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$151M |
| 3 |
Barclays
London,
United Kingdom
|
-$85.4M |
| 4 |
Citigroup
New York
|
-$37.3M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$25.3M |
IBB Hedge Fund Activity: Q3 2026 in Review
1,029 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2026, worth a combined $9.09B — up 17% from $7.76B a quarter earlier.
Buyers outnumbered sellers: 150 funds opened new IBB positions and 58 closed out — a net gain of 92 holders — while 295 added to existing stakes and 277 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $446M. The largest seller was Two Sigma Investments, cutting an estimated $297M.
- 1,029 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2026, up from 964 in Q2 2026.
- Funds reported $9.09B of iShares Biotechnology ETF stock for Q3 2026, up 17% quarter-over-quarter.
- 150 funds opened new iShares Biotechnology ETF positions in Q3 2026 and 58 closed out, a net change of +92 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2026 was Goldman Sachs, an estimated $446M added.
- The largest iShares Biotechnology ETF seller in Q3 2026 was Two Sigma Investments, an estimated $297M sold.
Based on aggregated 13F filings for Q3 2026.